AMGN
NASDAQ · Biotechnology
Amgen Inc
$384.32
+16.52 (+4.49%)
AMGN News9 articles
Merck Shares Drop on Insider Sale, Investors Await Key FDA Decision
Merck & Co. stock fell 3.5% amid an executive share sale and underperformance versus a broader market rally. Traders are focused on an upcoming FDA ruling for Keytruda's ovarian cancer expansion.
Dow Holds 50,000 as Markets Await Key Jobs, Inflation Data
The Dow Jones Industrial Average edged up 17 points to 50,132.79, maintaining its position above the 50,000 threshold. Investors are focused on upcoming employment and inflation reports, which could influence Federal Reserve policy.
Amgen Shares Slide on FDA Setback and Enbrel Weakness, Pressuring Dow
Amgen stock fell nearly 2% Monday, pressured by an FDA request to withdraw rare-disease drug Tavneos and a sharp 48% quarterly drop in Enbrel sales. The decline weighed on the price-weighted Dow Jones Industrial Average.
Merck Shares Slide 4% on Patent Concerns and 2026 Outlook
Merck & Co. stock fell nearly 4% Monday, underperforming the broader market as investors reacted to projected patent losses and a cautious 2026 sales forecast.
Dow Retreats from 50K Milestone as Investors Await Inflation, Jobs Data
The Dow Jones Industrial Average edged lower Monday after its historic close above 50,000, while the S&P 500 and Nasdaq gained on tech strength. Markets are focused on upcoming inflation and employment reports.
Johnson & Johnson Shares Retreat Amid Healthcare Sector Weakness
Johnson & Johnson stock declined 1.1% as healthcare stocks underperformed the broader market. Traders are eyeing upcoming U.S. jobs and inflation data for direction.
Dow Retreats Below 50,000 as Rotation Hits Tech; Key Economic Data Awaited
The Dow Jones Industrial Average fell below the 50,000 mark in Monday trading, pressured by a shift out of technology stocks. Investors await critical payrolls and inflation reports later this week.
Amgen Hits 52-Week Peak on Strong Earnings; Key Data, Dividend Date Ahead
Amgen shares surged 4.5% to a 52-week high of $384.32, fueled by robust quarterly results and a dividend declaration. Investors now await delayed U.S. jobs and inflation figures.
Amgen Reaches 52-Week Peak on Friday; Investors Eye Inflation Data and Drug Pricing
Amgen shares surged 4.5% to close at $384.32 on Friday, achieving a new 52-week high. Market participants are monitoring upcoming U.S. inflation figures and developments in drug pricing.